Mercy Health - Fairfield Hospital is the Only Hospital in the Cincinnati Region Participating in Groundbreaking Alzheimer's and Dementia Study

Mercy Health - Cincinnati, which provides advanced, compassionate, quality care in your neighborhood through its care network, announces that Paradigm Radiology, which provides imaging services for Mercy Health - Fairfield Hospital, has joined the Imaging Dementia — Evidence for Amyloid Scanning (IDEAS) Study.

Paradigm Radiology is the only participating radiology practice in Cincinnati and Columbus to be part of the study and it has designated Fairfield Hospital as its positron emission tomography (PET) scan facility. Fairfield Hospital is the only hospital in Greater Cincinnati participating in the study currently. Paradigm Radiology also intends have Mercy Health - Anderson, Clermont and West hospitals approved as IDEAS Study sites.

"The IDEAS Study is landmark research in our ability to differentiate Alzheimer's disease from other forms of dementia though imaging. Accurately diagnosing the cause of cognitive impairment and dementia through radiology can help direct therapy and lead to a care plan that improves patient safety and minimizes the risk of preventable complications," said Kevin Weber, MD, clinical leader and practicing nuclear radiologist at Paradigm Radiology. "We're thrilled our practice, in partnership with Mercy Health – Fairfield Hospital, was chosen as one of the facilities to conduct the study and believe the outcomes of this study will generate significant benefits for patients nationwide."

"The IDEAS Study will provide access to amyloid imaging to more than 18,000 Medicare beneficiaries age 65 and older meeting appropriate use criteria. This study is designed to help clarify the cause of the decline in patients' memory and thinking," said Thomas Urban, Mercy Health North Market President and CEO.

Patients interested in learning if they qualify should speak with their physician for referral to Fairfield Hospital for more information.

The IDEAS Study will assess whether, in diagnostically uncertain cases, amyloid PET scans help clinicians diagnose the cause of cognitive impairment and develop the most appropriate treatments and recommendations. It will enroll patients over 24 months at roughly 200 sites throughout the United States.

In April 2015, the Alzheimer's Association and the ACR announced the four-year research study. The purpose of the IDEAS Study is to examine how PET scans can help physicians improve health outcomes for their patients in cases where the cause of cognitive impairment is difficult to diagnose. The goal is to enable early and accurate diagnosis via PET scans to improve health outcomes, such as reducing unnecessary hospitalizations and emergency room visits, and increasing appropriate prescription of medications.

For more information about the IDEAS Study, please visit: www.ideas-study.org.